David Smil

661 University Avenue, West Tower
Toronto, ON M5G0A3, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 37 publications

Discovery and development of potent and selective dual NUAK/MARK inhibitors as Hippo pathway modulators for the treatment of cancer.

Discovery and development of potent and selective dual NUAK/MARK inhibitors as Hippo pathway modulators for the treatment of cancer.

Journal: European journal of medicinal chemistry

Published: January 27, 2026

Discovery of Two Highly Selective Structurally Orthogonal Chemical Probes for Activin Receptor-like Kinases 1 and 2.

Discovery of Two Highly Selective Structurally Orthogonal Chemical Probes for Activin Receptor-like Kinases 1 and 2.

Journal: Journal of medicinal chemistry

Published: July 18, 2024

Discovery of Conformationally Constrained ALK2 Inhibitors.

Discovery of Conformationally Constrained ALK2 Inhibitors.

Journal: Journal of medicinal chemistry

Published: March 18, 2024

A non-traditional crystal-based compound screening method targeting the ATP binding site of Plasmodium falciparum GRP78 for identification of novel nucleoside analogues.

A non-traditional crystal-based compound screening method targeting the ATP binding site of Plasmodium falciparum GRP78 for identification of novel nucleoside analogues.

Journal: Frontiers in molecular biosciences

Published: May 29, 2022

Probing the SAM Binding Site of SARS-CoV-2 Nsp14 In Vitro Using SAM Competitive Inhibitors Guides Developing Selective Bisubstrate Inhibitors.

Probing the SAM Binding Site of SARS-CoV-2 Nsp14 In Vitro Using SAM Competitive Inhibitors Guides Developing Selective Bisubstrate Inhibitors.

Journal: SLAS discovery : advancing life sciences R & D

Published: July 01, 2021

Leveraging Open Science Drug Development for PET: Preliminary Neuroimaging of 11C-Labeled ALK2 Inhibitors.

Leveraging Open Science Drug Development for PET: Preliminary Neuroimaging of 11C-Labeled ALK2 Inhibitors.

Journal: ACS medicinal chemistry letters

Published: March 02, 2021

Probing the SAM Binding Site of SARS-CoV-2 nsp14 in vitro Using SAM Competitive Inhibitors Guides Developing Selective bi-substrate Inhibitors.

Probing the SAM Binding Site of SARS-CoV-2 nsp14 in vitro Using SAM Competitive Inhibitors Guides Developing Selective bi-substrate Inhibitors.

Journal: bioRxiv : the preprint server for biology

Published: February 23, 2021

Rational Design and Synthesis of Selective PRMT4 Inhibitors: A New Chemotype for Development of Cancer Therapeutics*.

Rational Design and Synthesis of Selective PRMT4 Inhibitors: A New Chemotype for Development of Cancer Therapeutics*.

Journal: ChemMedChem

Published: January 08, 2021

Leveraging an Open Science Drug Discovery Model to Develop CNS-Penetrant ALK2 Inhibitors for the Treatment of Diffuse Intrinsic Pontine Glioma.

Leveraging an Open Science Drug Discovery Model to Develop CNS-Penetrant ALK2 Inhibitors for the Treatment of Diffuse Intrinsic Pontine Glioma.

Journal: Journal of medicinal chemistry

Published: August 14, 2020

Targeting ALK2: An Open Science Approach to Developing Therapeutics for the Treatment of Diffuse Intrinsic Pontine Glioma.

Targeting ALK2: An Open Science Approach to Developing Therapeutics for the Treatment of Diffuse Intrinsic Pontine Glioma.

Journal: Journal of medicinal chemistry

Published: May 06, 2020

Identification and characterization of the first fragment hits for SETDB1 Tudor domain.

Identification and characterization of the first fragment hits for SETDB1 Tudor domain.

Journal: Bioorganic & medicinal chemistry

Published: May 24, 2019

A chemical biology toolbox to study protein methyltransferases and epigenetic signaling.

A chemical biology toolbox to study protein methyltransferases and epigenetic signaling.

Journal: Nature communications

Published: February 20, 2018

Showing 1-12 of 37

Last Updated: 09/26/2026